1. Home
  2. HTD vs EOLS Comparison

HTD vs EOLS Comparison

Compare HTD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTD
  • EOLS
  • Stock Information
  • Founded
  • HTD 2004
  • EOLS 2012
  • Country
  • HTD United States
  • EOLS United States
  • Employees
  • HTD N/A
  • EOLS N/A
  • Industry
  • HTD Finance Companies
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTD Finance
  • EOLS Health Care
  • Exchange
  • HTD Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • HTD 819.5M
  • EOLS 1.1B
  • IPO Year
  • HTD N/A
  • EOLS 2018
  • Fundamental
  • Price
  • HTD $23.39
  • EOLS $16.63
  • Analyst Decision
  • HTD
  • EOLS Strong Buy
  • Analyst Count
  • HTD 0
  • EOLS 6
  • Target Price
  • HTD N/A
  • EOLS $22.60
  • AVG Volume (30 Days)
  • HTD 92.3K
  • EOLS 644.7K
  • Earning Date
  • HTD 01-01-0001
  • EOLS 11-05-2024
  • Dividend Yield
  • HTD 8.59%
  • EOLS N/A
  • EPS Growth
  • HTD N/A
  • EOLS N/A
  • EPS
  • HTD N/A
  • EOLS N/A
  • Revenue
  • HTD N/A
  • EOLS $237,260,000.00
  • Revenue This Year
  • HTD N/A
  • EOLS $34.62
  • Revenue Next Year
  • HTD N/A
  • EOLS $33.33
  • P/E Ratio
  • HTD N/A
  • EOLS N/A
  • Revenue Growth
  • HTD N/A
  • EOLS 40.71
  • 52 Week Low
  • HTD $16.17
  • EOLS $7.44
  • 52 Week High
  • HTD $22.13
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • HTD 62.43
  • EOLS 52.28
  • Support Level
  • HTD $23.06
  • EOLS $16.38
  • Resistance Level
  • HTD $23.43
  • EOLS $17.57
  • Average True Range (ATR)
  • HTD 0.29
  • EOLS 0.77
  • MACD
  • HTD -0.03
  • EOLS -0.04
  • Stochastic Oscillator
  • HTD 61.74
  • EOLS 42.51

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: